Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: This overview will look at the current evidence linking ADT and metabolic syndrome while discussing ongoing clinical trials under way assessing the effectiveness of metformin in abrogating these effects. The potential antineoplastic activity of metformin, mediated by multiple proposed mechanisms based on evidence from preclinical and clinical studies, will also be elucidated in this review. CONCLUSIONS: Overall available data support the potential dual benefit of metformin on ADT-induced metabolic syndrome and in its antineoplastic activity in prostate cancer, justifying the need for ongoing clinical trials to confirm these effects as the evidence currently available for standard practice is lacking.
|
Authors | A Clements, B Gao, S H O Yeap, M K Y Wong, S S Ali, H Gurney |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 22
Issue 12
Pg. 2556-2560
(Dec 2011)
ISSN: 1569-8041 [Electronic] England |
PMID | 21421541
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Hypoglycemic Agents
- Metformin
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Humans
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Insulin Resistance
- Male
- Metabolic Syndrome
(etiology, prevention & control)
- Metformin
(pharmacology, therapeutic use)
- Prostatic Neoplasms
(complications, therapy)
- Randomized Controlled Trials as Topic
|